BRAF and melanoma: Although both PTX and NCTD have been individually proposed as potential therapeutic agents against melanoma, the combined effects of these compounds on melanoma progression, particularly their impact on the expression and activation of key oncogenic signaling pathways such as PI3K/AKT, MAPK, BRAF, and mTOR, remain insufficiently understood [11,12].